KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.Int J Clin OncolPMID 41563650PMC129323472026-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study.J Prev Alzheimers Dis入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41564814PMC128592492026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
SARS-CoV-2 resistance analyses from the Phase 3 BIRCH study of obeldesivir in high-risk nonhospitalized participants with COVID-19.Antiviral ResPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41565160无 PMCID2026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease.J Prev Alzheimers Dis已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。PMID 41570392PMC128612072026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.Br J HaematolPMID 41571607PMC129955412026-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Bisoprolol to prevent adverse cardiac events (PACE) in COPD: a multicentre, double-blind, randomised, controlled, phase 3 trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41579873无 PMCID2026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Fibrinogen replacement to prevent intracranial hemorrhage in ischemic stroke patients after thrombolysis - a prospective randomized open blinded endpoint trial (FibER): rationale and methods.J Stroke Cerebrovasc Dis入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41581534无 PMCID2026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Original Study: Risk Factors for Early Recurrence in Patients With Biliary Tract Cancers Who Underwent Curative Resection: An Exploratory Subgroup Analysis of JCOG1202.J Surg Oncol入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。PMID 41588936无 PMCID2026-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Hydroxocobalamin, thiamine, and pyridoxine as an adjunct to standard treatment in chronic low back pain: a randomized clinical trial.Med Clin (Barc)PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41604864无 PMCID2026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.Obesity (Silver Spring)疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 other;FIGURE 3:非 KM 图。PMID 41612966PMC129332292026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41616799无 PMCID2026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma.Dig Liver Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41622055无 PMCID2026-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 10 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Extended Data Fig. 1:AI 判定为 multi panel km;Extended Data Fig. 2:非 KM 图;另有 5 张未列出。PMID 41634391PMC130046862026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Early onset radiation-induced leukoencephalopathy in patients treated for a glioblastoma by STUPP protocol and risk factors evaluation, an ancillary study of the phase III ASTER protocol.Rev Neurol (Paris)PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41644378无 PMCID2026-Mar0.85The record describes an ancillary study of the ASTER phase III trial focusing on the incidence and risk factors of early-onset radiation-induced leukoencephalopathy. While it originates from a randomized, phase III trial with a drug intervention, the analysis is not a primary report of a time-to-event efficacy endpoint (e.g., OS, PFS). The study's primary outcome is a safety/toxicity measure (incidence of RIL), and the report type is 'other' (ancillary analysis), not the primary efficacy result.无 KM 图
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41655576无 PMCID2026-Mar0.95The record describes a randomized Phase III trial with a primary time-to-event endpoint (failure-free survival), but the intervention is radiotherapy alone, not a drug-containing intervention. Therefore, it does not meet the drug-intervention criterion for inclusion in the oncology Kaplan-Meier digitization cohort.无 KM 图
Inpatient initiation of tuberculosis preventive therapy with 1 month of isoniazid and rifapentine for adults with advanced HIV disease and cryptococcal meningitis (IMPROVE): a non-inferiority, randomised controlled trial.Lancet HIV疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1::CONSORT/入组流程图;Figure 2a::AI 判定为 forest plot;Figure 2b::森林图/亚组分析图。PMID 41662846PMC130475592026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41671628无 PMCID2026-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41671629无 PMCID2026-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.Clin TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41672793无 PMCID2026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.ESMO OpenPMID 41687160PMC129251082026-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial.Lancet HIV已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:ROC 图。PMID 41687672PMC133325172026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41690202无 PMCID2026-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41698381无 PMCID2026-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Immunogenicity, Safety and Immune Persistence of Sabin Strain Inactivated Poliovirus Vaccine: A Phase III Clinical Trial.Scand J ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41714818无 PMCID2026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Safety and efficacy of intensive task-specific training in people with recent spinal cord injury: a phase 3, pragmatic, randomised, assessor-blinded, superiority trial.Lancet NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41722590无 PMCID2026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study.Lancet NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41722591无 PMCID2026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.ESMO OpenPMID 41747585PMC129556602026-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.ESMO Open已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:生活质量量表图;Figure 2:生活质量量表图;Figure 3:生活质量量表图。PMID 41747587PMC129556792026-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Trial.Future Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1.:生活质量量表图。PMID 41778625PMC129772702026-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
PRehab tO PreparE Living Liver Donors for Enhanced Recovery (PROPELLER): A Feasibility Randomized Controlled Trial.Clin Transplant入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41782467PMC129614202026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Quality-of-life outcomes with pimitespib in patients with advanced gastrointestinal stromal tumor: results from the randomized, double-blind, placebo-controlled, phase III, CHAPTER-GIST-301 study.ESMO OpenPMID 41785671PMC129729822026-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.Lancet Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41791832无 PMCID2026-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.Future Oncol已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 flow diagram。PMID 41793151PMC129806542026-Mar0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT.Health Technol Assess疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41797548PMC129899042026-Mar0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial.JCO Glob OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41812092无 PMCID2026-Mar0.98未发现恶性肿瘤人群证据。无 KM 图
Effects of Exercise on Cognitive Impairment in Patients Receiving Chemotherapy: A Multicenter Phase III Randomized Controlled Trial.J Natl Compr Canc NetwPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41825129无 PMCID2026-Mar0.45The study is a Phase III randomized trial in oncology patients receiving chemotherapy, but its primary endpoints are cognitive impairment and mental fatigue (measured by questionnaires), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or analysis using Kaplan-Meier or HR. Therefore, it does not meet the eligibility criterion for a time-to-event endpoint.无 KM 图
Effect of Equine-assisted Biographical Work (EABW) in older adults with subclinical depression: a randomized controlled trial.BMC Complement Med Ther已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other。PMID 41761195PMC130594252026-Feb-280.98未发现恶性肿瘤人群证据。无 KM 图
Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study.J Headache Pain已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。PMID 41761058PMC129618722026-Feb-270.98未发现恶性肿瘤人群证据。无 KM 图
Prophylactic LYMphatic Reconstruction (LYMbR) to prevent lymphedema after node dissection for cutaneous malignancies: a randomized controlled trial.Trials入排复审未纳入:The record is a protocol for a Phase III randomized trial in oncology (cutaneous malignancies) with a surgical (non-drug) intervention. It lacks results and does not specify a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it is excluded.PMID 41749241PMC131961682026-Feb-260.85The record is a protocol for a Phase III randomized trial in oncology (cutaneous malignancies) with a surgical (non-drug) intervention. It lacks results and does not specify a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it is excluded.无 KM 图
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients.Clin Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:非 KM 图;Figure 1.:研究设计图;Figure 2.:非 KM 图;Figure 3.:AI 判定为 other;Figure 4.:非 KM 图;另有 1 张未列出。PMID 41321121PMC130169652026-Feb-250.98未发现恶性肿瘤人群证据。无 KM 图
Minimum 18-week chemotherapy improves survival in locally advanced rectal cancer after neoadjuvant radiotherapy: a post hoc analysis of the STELLAR trial.BMC Med入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。PMID 41742206PMC130414752026-Feb-250.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41653933PMC130059602026-Feb-210.98未发现恶性肿瘤人群证据。无 KM 图
Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41655588无 PMCID2026-Feb-210.98未发现恶性肿瘤人群证据。无 KM 图
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图。PMID 41353787PMC129042402026-Feb-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG A1.:森林图/亚组分析图;FIG A2.:森林图/亚组分析图。PMID 41363773PMC129042242026-Feb-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.J Clin OncolPMID 41512237PMC131923322026-Feb-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.N Engl J MedPMID 41363801PMC132187382026-Feb-190.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.J Immunother CancerPMID 41714113PMC129273462026-Feb-190.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease.J Neurol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41708985PMC129165152026-Feb-180.98未发现恶性肿瘤人群证据。无 KM 图
Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41360717PMC126872032026-Feb-170.98未发现恶性肿瘤人群证据。无 KM 图